Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

Journal Articles

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Blood (2015) 126 (23): 53.

https://doi.org/10.1182/blood.V126.23.53.53

Published: 2015

Journal Articles

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Giovannino Silvestri, PhD, Justin Ellis, Lorenzo Stramucci, PhD, Jason G Harb, PhD, Paolo Neviani, PhD, Guido Marcucci, MD, Denis-Claude Roy, MD, Peter Hokland, MD DMSc, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M Livak, PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2014) 124 (21): 4529.

https://doi.org/10.1182/blood.V124.21.4529.4529

Published: 2014

Journal Articles

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Blood (2013) 122 (17): 3034–3044.

https://doi.org/10.1182/blood-2013-04-495374

Published: 2013

Includes: Supplemental data

Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Blood (2013) 122 (11): 1923–1934.

https://doi.org/10.1182/blood-2013-03-492181

Published: 2013

Includes: Supplemental data

Journal Articles

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Gregory Ferenchak, Justin Ellis, Guido Marcucci, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Danilo Perrotti, MD, Ph.D

Blood (2012) 120 (21): 35.

https://doi.org/10.1182/blood.V120.21.35.35

Published: 2012

Journal Articles

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 773.

https://doi.org/10.1182/blood.V120.21.773.773

Published: 2012

Journal Articles

Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1 + in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34 + /CD38 − Stem and CD34 + progenitor Cells From CML-BC Patients

Jason G Harb, Ph.D, Paolo Neviani, PhD, Claudia S Huettner, PhD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2738.

https://doi.org/10.1182/blood.V118.21.2738.2738

Published: 2011

Journal Articles

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, PhD, S. A Saddoughi, Paolo Neviani, PhD, Jason G Harb, Ph.D, Besim Ogretmen, PhD, Robert Bittman, Ph.D, Ross L Levine, MD, Alfonso Quintás-Cardama, MD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2494.

https://doi.org/10.1182/blood.V118.21.2494.2494

Published: 2011

Journal Articles

Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, PhD, Jason G Harb, Ph.D, Carolyn Paisie, B.S., Guido Marcucci, MD, Sharon Shacham, PhD, Michael Kauffman, MD, Ph.D., Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 3758.

https://doi.org/10.1182/blood.V118.21.3758.3758

Published: 2011

Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 2901.

https://doi.org/10.1182/blood.V116.21.2901.2901

Published: 2010

Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 775.

https://doi.org/10.1182/blood.V116.21.775.775

Published: 2010

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Jason G Harb, Paolo Neviani, Joshua J Oaks, Guido Marcucci, MD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 1222.

https://doi.org/10.1182/blood.V116.21.1222.1222

Published: 2010

Journal Articles

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

Jason Harb, PhD, Paolo Neviani, PhD, Claudia Huettner, PhD, Guido Marcucci, MD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 191.

https://doi.org/10.1182/blood.V114.22.191.191

Published: 2009

Journal Articles

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Blood (2009) 114 (22): 855.

https://doi.org/10.1182/blood.V114.22.855.855

Published: 2009

Journal Articles

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

Joshua Oaks, BS, Paolo Neviani, PhD, A. Mukhopadhyay, Ramasamy Santhanam, PhD, Y. Ma, Charlene Mao, Guido Marcucci, MD, Ching-Shih Chen, Jorge Cortes, MD, Michael A. Caligiuri, M.D., Peter Hokland, Sr., Claudia Huettner, PhD, Steffen Koschmieder, MD, Jose Cancelas, MD, PhD, Roger Briesewitz, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Besim Ogretmen, PhD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 3259.

https://doi.org/10.1182/blood.V114.22.3259.3259

Published: 2009

Journal Articles

Src homology 2 domain–containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ- MiR-155 transgenic mice

Stefan Costinean, Sukhinder K. Sandhu, Irene M. Pedersen, Esmerina Tili, Rossana Trotta, Danilo Perrotti, David Ciarlariello, Paolo Neviani, Jason Harb, Lauren Rachel Kauffman, Aaditya Shidham, Carlo Maria Croce

Blood (2009) 114 (7): 1374–1382.

https://doi.org/10.1182/blood-2009-05-220814

Published: 2009

Includes: Supplemental data

Journal Articles

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals

Paolo Neviani, PhD, Ramasamy Santhanam, Ph.D, Yihui Ma, B.S., Guido Marcucci, MD, John C. Byrd, MD, Ching-Shih Chen, Ph.D, Jorge Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Danilo Perrotti, MD, PhD

Blood (2008) 112 (11): 189.

https://doi.org/10.1182/blood.V112.11.189.189

Published: 2008

Journal Articles

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Anna M. Eiring, Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Ji Suk Chang, Mario Notari, William Willis, Carlo Gambacorti-Passerini, Stefano Volinia, Guido Marcucci, Michael A. Caligiuri, Gustavo W. Leone, Danilo Perrotti

Blood (2008) 111 (2): 816–828.

https://doi.org/10.1182/blood-2007-05-090472

Published: 2008

NARROW

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1 + in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34 + /CD38 − Stem and CD34 + progenitor Cells From CML-BC Patients

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

Src homology 2 domain–containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ- MiR-155 transgenic mice

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only